Long term treatment with omalizumab in adolescent with refractory solar urticaria.

Mauro IannelliStefano PassanisiGiuseppe CrisafulliStefania ArasiLucia CaminitiGiuseppina ZirilliGiovanni Battista Pajno

Published in: Italian journal of pediatrics (2021)

Our experience confirms the effectiveness and safety of omalizumab for the management of refractory solar urticaria. Future studies are awaited in order to monitor long term effects and chronic doses of this treatment, particularly in patients who need concomitant therapy with antihistamines.

Keyphrases

young adults
mental health
stem cells
replacement therapy
combination therapy
bone marrow
childhood cancer